A pilot study into bosentan (Tracleer®) as an immunomodulating agent in patients with Behçet's disease Vrije Universiteit Brussel
BACKGROUND: Behçet's disease (BD) is an auto-inflammatory vasculitis characterized by aphthous oro-genital ulcers, inflammatory skin changes and uveitis. Treatment is mainly immunosuppressive. Interestingly, elevated endotheline-1 (ET-1) levels suggest a possible beneficial effect of treatment with an ET-1 receptor antagonist.
OBJECTIVE: The aim of our study was to investigate the possible beneficial effect of the ET-1 inhibitor ...